Ligand Pharma announces positive results from trial of CE-Iohexol
Category: #health  By Pankaj Singh  Date: 2019-07-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ligand Pharma announces positive results from trial of CE-Iohexol

Ligand Pharmaceuticals, a US-based biopharmaceutical company recently announced positive top line results from clinical trial of its internal CE (Captisol-enabled) Iohexol program. The study attained primary endpoint indicating pharmacokinetic bioequivalence between OMNIPAQUE™ & Captisol-enabled Iohexol, cite sources.

For the record, Iohexol is a commonly used injectable diagnostic contrast agent for imaging procedures and has global sales that amount to more than $500 million with no generic competition in the U.S.

The Captisol-enabled Iohexol program was established in January 2018 to develop a next-gen contrast agent for diagnostic imaging that poses a decreased risk of renal toxicity. Based on data, the trial attained the primary endpoint indicating pharmacokinetic bioequivalence between OMNIPAQUE™, a reference Iohexol injection & CE-Iohexol injection after intravenous administration in healthy adults.

Captisol-enabled Iohexol injection was safe & well tolerated, adverse events were confined to established OMNIPAQUE safety profile. The details & data from the Phase 1 trial have been submitted for presentation at future scientific conferences.

John Higgins, CEO, Ligand, was reported to say that the Ligand team has executed the trial ahead of schedule. The company is looking forward to continuing development of Captisol-enabled Iohexol with the goal to advance it for additional studies to support a registration filing. He added, saying that after the data is published by the end of this year, the company has plans to explore potential commercial partnerships for this program.

Peter A. McCullough, President, Cardiorenal Society of America and MD, Vice Chief of Medicine, Baylor University Medical Center, Dallas, was reportedly quoted saying that this trial signifies a promising milestone that seeks safer agent for patients who are administered with intravenous contrast for their radiology & cardiology tests.

Top line results from the trial showed that this product which incorporates a patented formulation ingredient had the anticipated pharmacokinetic profile compared to the reference standard agent, and potentially offers less kidney injury when administered to patients with baseline kidney disease, diabetes, & multiple associated risk factors, McCullough added.

Source credits: https://investor.ligand.com/press-releases/detail/387/ligand-announces-positive-top-line-results-from-phase-1

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
Rocket Pharma unveils Phase 1/2 trial data for its Fanconi Anemia drug
By Pankaj Singh

The manuscript includes data of the first four trial participants that were treated with RP-L102 under the Phase 1/2 FANCOLEN-I study.   First RP-L102 trail data demonstrates increase in bone marrow engraftment levels, which further leads to...

Shopify buys 6 River Systems for $450M to grow its fulfillment network
Shopify buys 6 River Systems for $450M to grow its fulfillment network
By Pankaj Singh

Acquisition of 6 River Systems seems to be an attempt to accelerate the growth in delivery of daily packages. The deal would further expand the reach of the Shopify Fulfillment Network, which utilizes machine learning to ensure lower shipping cost...

Genentech to present new data from neuroscience portfolio at ECTRIMS
Genentech to present new data from neuroscience portfolio at ECTRIMS
By Pankaj Singh

The data from the neuroscience portfolio would be showed at the 35th ECTRIMS between September 11 and 13 in Stockholm.   The presentations would include entire Phase III outcomes from the SAkuraStar trial investigating satralizumab as a Neur...